EGFR wild-type non-small cell lung cancer (NSCLC) cell lines regained sensitivity to EGFR tyrosine kinase inhibitors when EMT was inhibited by miR-200c overexpression [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.